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per year. CHD may adversely impact on the Quality of Life. The
objectives of the study were to describe Health-Related Quality
of Life (HR-QOL) in subjects with CHD and to compare their
health state with the health state of subjects without CHD.
METHODS: We selected subjects with CHD (Cases) from a rep-
resentative sample of the Italian general population aged from
40 to 79 years, enrolled in a population based naturalistic
prospective survey. We matched each of them by age and sex
with subjects without CHD disease (Controls). EuroQoL (EQ-
5D) was used to evaluate HR-QOL. We used Chi Square Test to
evaluate differences in the ﬁve dimensions of the EQ-proﬁle
between the two groups. Paired sample T test was used to eval-
uate differences in EQ-VAS. RESULTS: We analyzed two groups
of 98 subjects per group. The mean age was 64.7 (SD 8.6) years,
(69.4%) were male. More problems were reported in cases than
in controls in the mobility dimension, usual activities, and self
care and anxiety/depression dimensions. These differences
proved statistically signiﬁcant. Whereas in pain/discomfort
domain there was no signiﬁcant difference between the two
groups. Mean values of the visual analogue scale assessing global
health status indicated by case and control were 68.1 and 66.94,
respectively (P = 0.005). CONCLUSION: The study, comparing
subjects of the same age and sex with and without CHD, sug-
gests that the presence of CHD is associated with higher prob-
lems in HR.
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OBJECTIVES: This study aims to describe the health related
quality of life (HRQOL) of the Portuguese population and inves-
tigates sociodemographic differences. METHODS: Subjects ran-
domly selected from the Portuguese active population (n = 2459)
were assessed using the SF-36, a generic measure of HRQOL,
which was converted into the preference-based SF-6D, following
the Brazier algorithm. Although the sample was randomly
selected, it differed slightly from the whole population. In order
to correct this, post-stratiﬁed statically techniques were used to
weight the initial results by gender and age, according to the pop-
ulation values. RESULTS: Mean global utility SF-6D scores were
0.70, and ranged from 0.73 (18–24 years) to 0.63 (55–64 years).
The mean utility scores were 0.17 lower in the lower educational
level than in the higher educational level (p < 0.000). Women,
people living in rural areas and the elderly reported lower levels
of utility scores. Nonparametric tests showed that health utility
values were signiﬁcantly related to employment (p < 0.000): the
unskilled manual workers (0.68) reported lower utility values
than the non-manual workers (0.74). For different diseases mean
utility scores ranged from 0.66 (hepatitis) to 0.56 (stroke). This
study was able to achieve normative data by age and gender for
the SF-6D. Using QALYs as outcome measures, the difference
between unskilled manual workers and non-manual workers
would be equivalent to a difference of 4902€ in annual income.
In this line of thinking, the difference between lower educational
level and higher educational level would be equivalent to a 
difference of 13,889€ in annual income. CONCLUSION: We
conclude that the SF-6D is an efﬁcient tool for measuring the
HRQOL in the community, so that different population groups
can be compared. The preference-based utility measure used
seems to adequately discriminate across different sociodemo-
graphic differences, showing that the HRQOL varies greatly
between sociodemographic groups.
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OBJECTIVES: To evaluate current lipid management practice in
The Netherlands and estimate the impact of new guidelines of
the European Society of Cardiology (ESC) on cholesterol goal
attainment. METHODS: Data were obtained from a sample of
the PHARMO system that includes complete medication, hospi-
tal admission and clinical lab assessment data of 80,000 Dutch
residents. Patients starting lipid lowering drug (LLD) therapy
between 2002–2004 who had a baseline TC measurement in the
six months prior to initiation of therapy and had at least one TC
measurement after the start of therapy were included. Goal
attainment was compared using the ESC 1998 and ESC 2003
guidelines. For both guidelines goal attainment was in general
deﬁned as TC <5mmol/l during LLD treatment. However, in 
the ESC 2003 guidelines goal attainment was deﬁned as TC 
<4.5mmol/l during LLD treatment for patients with cardiovas-
cular disease or diabetes. Doses of statins were expressed in
equipotencies based on TC lowering capabilities. RESULTS: The
study sample comprised of 623 patients (43% females). Most
patients (83%) were initiated on statin monotherapy of at least
an equipotent dose of four (simvastatin 20mg or equipotent
statin). Overall TC goal attainment rate based on 1998 guide-
lines was 59% and based on new ESC guidelines was 49%. Goal
attainment in patients with cardiovascular disease or diabetes
changed from 69% to 49% based on old and new guidelines
respectively. Our results also indicated that persistent statin use
during follow-up increased goal attainment (54% versus 44% in
not persistent patients using new ESC guidelines). CONCLU-
SIONS: Though lipid management in recent years has become
more aggressive, achievement of cholesterol goals based on the
new ESC guidelines is relatively low. Therefore there is a need
for highly effective lipid lowering therapies that are also well tol-
erated in order to achieve sufﬁcient persistence.
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OBJECTIVES: To compare lipid management and reductions in
total cholesterol (TC) levels among patients initiated on lipid
lowering drugs (LLD) in recent years (2002–2004) to those ini-
tiated in earlier years (1991–2001). METHODS: Data were
obtained from a sample of the PHARMO system that includes
complete medication, hospital admission and clinical lab assess-
ment data of 80,000 Dutch residents. Patients starting LLD
therapy and having a baseline TC measurement within six
months prior to therapy initiation as well as at least one mea-
surement after the start of therapy were included in two study
cohorts. One cohort included patients who initiated therapy in
2002–2004 and another that initiated therapy in 1991–2001.
Goal attainment was deﬁned as TC <5mmol/l during LLD treat-
ment according to Dutch guidelines. Statin dosage was expressed
in equipotencies based on TC lowering capabilities. RESULTS:
Patients with cholesterol levels <6mmol/l were more likely to be
treated in the period 2002–2004 than in the period 1991–2001
(27% versus 15% of all patients, respectively). Furthermore,
equipotent dose at the start of statin monotherapy gradually
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increased over the years; in 1996 13.7% of the patients started
with at least an equipotent dose of four (simvastatin 20mg or
equipotent) while in 2004 88.4% of all patients started on at
least an equipotent dose of four. Goal attainment increased from
42% in years prior to 2001 to 59% in 2002–2004 and was high
in patients with cardiovascular disease and diabetes (43% versus
69%). CONCLUSIONS: Although in recent years aggressive
statin treatment and lower baseline TC levels led to higher goal
attainment 41% of the patients still did not reach goal. There-
fore even more effective and well tolerated lipid lowering thera-
pies seem to be required.
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OBJECTIVES: To analyse the cost-effectiveness of Rosuvastatin
compared to Atorvastatin in the treatment of hypercholes-
terolemia and prevention of ischemic heart disease (IHD) in 
Portugal. METHODS: A probabilistic Markov model was devel-
oped to analyse the costs and consequences of lifetime treatment
with Rosuvastatin and Atorvastatin. For this purpose, results
from head-to-head, randomised, double-blind trials evaluating
low-density lipoprotein (LDL) changes and from a meta-analy-
sis deﬁning the relationship between LDL levels and fatal and
non-fatal IHD events were combined. Incidence of myocardial
infarction was derived from a nine-year Portuguese observa-
tional study. Death rates due to IHD and other causes were
obtained from ofﬁcial data. Resource use in the treatment of MI
was estimated by a Delphi panel of 8 Portuguese cardiologists
with at least 15 years of clinical practice. Calculation of costs
was done on both the societal and patients’ perspectives. Eligi-
ble population was deﬁned as untreated individuals over 35 years
of age with LDL above 160mg/dl. RESULTS: Rosuvastatin
slightly increases life expectancy: 5.64 days per patient and 8832
years for the eligible population. Although the drug is more
expensive, economic analysis shows that Rosuvastatin is cost
saving. It saves €105 or €57 per patient on the society’s or the
patients’ perspective, respectively. Therefore, Rosuvastatin dom-
inates the alternative having a cost-effectiveness ratio of -€6772
and -€3682 per life year according to the society’s or the
patients’ perspectives. In the 10,000 simulations carried out
Rosuvastatin was always more efﬁcacious than Atorvastatin,
being cost saving in 56.05% of the cases. If the willingness to
pay is higher than €162 (society) or €98 (patients) Rosuvastatin
is cost-effective in all cases. CONCLUSION: Rosuvastatin dom-
inates Atorvastatin in the prevention of IHD in Portugal.
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While treatment guidelines recommend lowering cholesterol 
to target levels, many remain above recommended goal (TC 
>4.5mmol/dl for CHD and diabetic patients). In a clinical trial
patients switched from statin monotherapy to Ezetimibe/Sim-
vastatin (dual inhibition therapy) experienced an additional
27.5% and an 18.8% reduction in LDL-C and TC, respectively.
OBJECTIVE: Assess cost-effectiveness of switching patients to
Ezetimibe/Simvastatin (followed by titration on Ezetimibe/
Simvastatin) versus an atorvastatin dose titration strategy in
CHD/diabetic patients who are not at goal with atorvastatin
monotherapy. METHODS: Previously published decision-ana-
lytic model was used to project lifetime costs and beneﬁts of lipid
therapy. Clinical trial data were used in the model to estimate
TC reductions for different treatment strategies. The effect of TC
reductions on CHD event rates was estimated using Framingham
equations and Finnish statistics on nonCHD-related mortality.
Direct costs of CHD events in Finland [Health 2000 Survey data
at the 2003 price level and also from the literature], Finnish
prices for atorvastatin and Ezetimibe/Simvastatin and age spe-
ciﬁc quality-of-life weights were used to project cost/QALY. The
model was run for a sample of Finnish CHD/diabetic patients
(N = 25) that participated in the Finrisk 2002 study and were
not at TC goal while on therapy with atorvastatin and having
data on all Framingham risk factors. RESULTS: The mean age
of the study sample was 60.4 (SD 7.7) years, 60% male, lipid
proﬁle on atorvastatin TC 5.4 (SD 0.9) mmol/L, HDL-C 1.3 (SD
0.3) mmol/L, triglycerides 1.8 (SD1.1) mmol/L. Switching to 
Ezetimibe/Simvastatin (followed by 11% titration on Ezetimibe/
Simvastatin) compared to atorvastatin titration (11%) is pro-
jected to increase undiscounted life expectancy by 0.75 years for
CHD/diabetic patients with a discounted incremental cost/QALY
of €9172. CONCLUSION: Switching to dual inhibition therapy,
(Ezetimibe/Simvastatin) in CHD/diabetic patients not at goal on
atorvastatin is projected to be a cost-effective alternative to ator-
vastatin titration.
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OBJECTIVES: The aim of this study was to collect comparable
and reliable data on the lipid lowering therapy in Slovakia during
the period 1996–2004. The special interest was paid to the trend
of the statin and ﬁbrate usages. METHODS: Data of wholesalers
(following ATC/DDD), who are legally obliged provide this
information to the Slovak Institute for Drug Control, was used
for the analysis. The results were expressed in the numbers of
the packages, ﬁnance units (€) and deﬁned daily doses per 1000
inhabitants per day (DID). RESULTS: The collected data showed
large increases in hypolipidemic consumption from 1996 to 2004
in term of DID (in 1996 (4.18), in 2000 (12.79) and in 2004
(31.50)). A signiﬁcant increase in statin consumption (in 1996
(1.97), in 2000 (6.27) and in 2004 (22.33)) and slight increase
in ﬁbrate consumption (in 1996 (3.59), in 2000 (6.38) and in
2004 (9.13)) in term of DID can be seen from this analysis. From
the reimbursement point of view, simvastatin (in 2000 was reim-
bursed at the level of €0.84 per DDD, in 2004 the reimburse-
ment level was at €0.24), ﬂuvastatin (in 2000 was reimbursed at
the level of €0.75 per DDD, in 2004 the reimbursement level was
at €0.47), atorvastatin (in 2000 was reimbursed at the level of
€0.89 per DDD, in 2004 the reimbursement level was at €0.51).
Financial expenditures were for statins (in 1996 (€989,000), in
2000 (€10,335,000) and in 2004 (€13,043,000)) and for ﬁbrates
(in 1996 (€2,743,000), in 2000 (€4,546,000) and in 2004
(€4,478,000)). CONCLUSIONS: Usage of generic drugs for the
treatment of hypercholesterolemia brought about a dramatic
increase in hypolipidemic consumption and the ﬁnancial expen-
